Biogen teams up with gene-editing startup Scribe on ALS programme
pharmaphorum
OCTOBER 8, 2020
Scribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 million deal with Biogen. Its main platform – called X-editing – can generate CRISPR drugs with improved activity, specificity and deliverability compared to rivals, according to the start-up’s website.
Let's personalize your content